Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03654716 |
Recruitment Status :
Completed
First Posted : August 31, 2018
Last Update Posted : August 14, 2023
|
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
TeamConnor Childhood Cancer Foundation
Cookies for Kids' Cancer
Aileron Therapeutics, Inc.
Information provided by (Responsible Party):
David S Shulman, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | July 17, 2023 |
Actual Study Completion Date : | July 17, 2023 |